Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX   US92532F1003

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vertex Pharmaceuticals Inc
Discovers and develops novel, small molecule pharmaceuticals

Vertex Pharmaceuticals, Inc. is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs.

The company's research focuses on cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis.

Its product pipe line includes NCIVEK (telaprevir), which is marketed in the U.S. and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection; and KALYDECO (ivacaftor), which it markets in the U.S., Canada and Europe for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation that is referred to as the G551D mutation.

The company's other drug candidates include ivacaftor, VX-809, VX-661, VX-135, VX-222, VX-509 and VX-787.

Vertex Pharmaceuticals was founded by Boger S. Joshua in 1989 and is headquartered in Cambridge, MA.

Number of employees : 1 800 persons.
Sales per Businesses
20122013Delta
USD (in Million)%USD (in Million)%
Pharmaceuticals1,527100%1,212100% -26%
Sales per Regions
20122013Delta
USD (in Million)%USD (in Million)%
United States1,37489.9%896.9574% -53.13%
Europe129.798.5%279.5623.1% +53.57%
Other23.741.6%35.472.9% +33.06%
United Kingdom-----
Managers
NameAgeSinceTitle
Jeff M. Leiden PhD, MD582009Chairman, President & Chief Executive Officer
Ian F. Smith482001Chief Financial Officer & Executive Vice President
Jeffrey A. Chodakewitz, MD-2014Chief Medical Officer & Senior Vice President
Matthew W. Emmens622004Director
Joshua S. Boger, PhD621989Director
Bruce I. Sachs, MBA541998Co-Lead Independent Director
Elaine S. Ullian661997Co-Lead Independent Director
Wayne Joseph Riley MD, MBA542010Independent Director
Margaret G. McGlynn, MBA542011Independent Director
Terrence C. Kearney, MBA592011Independent Director
Shareholders
NameShares%
Capital Research & Management Co. (World Investors) 25,657,17710.7%
Wellington Management Co. LLP 19,858,4608.26%
The Vanguard Group, Inc. 17,236,3337.17%
T. Rowe Price Associates, Inc. 14,190,7625.90%
Fidelity Management & Research Co. 13,979,1575.81%
BlackRock Fund Advisors 11,800,4604.91%
Jennison Associates LLC 10,448,7524.34%
SSgA Funds Management, Inc. 9,753,7614.06%
JPMorgan Investment Management, Inc. 8,768,3003.65%
Columbia Management Investment Advisers LLC 8,387,6303.49%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Biopharmaceuticals
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
GILEAD SCIENCES, ..
AMGEN, INC.
ABBVIE INC
CELGENE CORPORATI..
BIOGEN IDEC INC
ASTRAZENECA PLC
ALEXION PHARMACEU..
VERTEX PHARMACEUT..
UCB
GRIFOLS SA
JAZZ PHARMACEUTIC..
CHONGQING ZHIFEI ..
-
BEIJING TIANTAN B..
-
CELLDEX THERAPEUT..
MEDY TOX INC
AUXILIUM PHARMACE..
WALVAX BIOTECHNOL..
-
GREEN CROSS CORP
THERAVANCE INC
ABCAM PLC
Sector Pharmaceuticals
Company contact information
50 avenue Northern
US-MA 02110 Boston, Massachusetts
États-Unis (les)

Phone : +1 617 444 6100
Fax : +1 617 444 6680
Internet : http://www.vpharm.com
Markets and indexes
- NASDAQ All Markets
- Nasdaq Global Select Market
- Nasdaq 100 / SP500
Stock Exchange Codes
- ISIN Code :  US92532F1003
- Bloomberg Code :  VRTX:US
- Reuters Code :  VRTX.O
- Datastream Code :  
© 2015 Factset    © 2015 Cofisem   
Dynamic quotes  
ON
| OFF